Clinical Trial Update: Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating methylphenidate hydrochloride to reduce fatigue in prostate cancer patients receiving hormone therapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Prostatic Neoplasms, Fatigue | Phase 2 | Status: TERMINATED